Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer

NCT06712472 is registered in ClinicalTrials.gov with Gustave Roussy, Cancer Campus, Grand Paris as lead sponsor.

NCT NCT06712472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06712472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Phase
Phase 3
Overall status
Recruiting
Start date
June 26, 2024
Completion date
December 31, 2031
Enrollment
554 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, p53abn